Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

AUTOLUS THERAPEUTICS PLC

(AUTL)
  Report
Delayed Nasdaq  -  04:00 2022-12-09 pm EST
1.850 USD   -38.13%
04:14pSector Update: Health Care Stocks Sputter at Close
MT
02:16pTop Midday Decliners
MT
01:46pSector Update: Health Care Stocks Losing Strength in Friday Trade
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Autolus Therapeutics Shares Jump After Cancer-Collaboration Agreement with Bristol Myers

10/04/2022 | 06:02am EST

By Sabela Ojea


Shares of Autolus Therapeutics Ltd. on Tuesday rose 14% after the U.K. leukemia drug maker announced the signing of collaboration agreement for the treatment of cancer with pharmaceutical company Bristol Myers Squibb Co.

In premarket trading, the stock was up $2.49 after it closed at $2.18 Monday. The shares have fallen more than 50% so far this year.

The biopharmaceutical will receive an upfront payment from Bristol Myers, with the potential to exercise option fees, development milestone payments and royalties, the company said without disclosing details.

Through the agreement, Autolus said it will grant Bristol Myers access to its Rituximab Safety Switch RQR8 to develop a selection of cell therapy programs for the treatment of cancer.

Bristol Myers will have the option to incorporate the RQR8 safety switch in additional cell therapy programs beyond the initial set of selected programs, the company said.


Write to Sabela Ojea at sabela.ojea@wsj.com


(END) Dow Jones Newswires

10-04-22 0802ET

Stocks mentioned in the article
ChangeLast1st jan.
AUTOLUS THERAPEUTICS PLC -38.13% 1.85 Delayed Quote.-42.39%
BRISTOL-MYERS SQUIBB COMPANY -1.31% 78.83 Delayed Quote.28.20%
CORN FUTURES (ZC) - CBE (ELECTRONIC)/C1 0.32% 634 End-of-day quote.6.53%
All news about AUTOLUS THERAPEUTICS PLC
04:14pSector Update: Health Care Stocks Sputter at Close
MT
02:16pTop Midday Decliners
MT
01:46pSector Update: Health Care Stocks Losing Strength in Friday Trade
MT
11:52aFTSE 100 Closes Friday Up on China Reopening, Rally Hopes
DJ
11:05aEuropean Equities Rise Modestly Friday, But End Week Lower
MT
10:09aInterContinental Hotels Shares Have Been 'Left Behind'
DJ
09:39aNeedham Lowers Price Target on Autolus Therapeutics to $7 From $12, Maintains Buy Ratin..
MT
09:13aSector Update: Health Care Stocks Steady Premarket Friday
MT
07:53aTop Premarket Decliners
MT
07:32aSterling Stays Higher After BOE Inflation Expectations Survey
DJ
More news
Analyst Recommendations on AUTOLUS THERAPEUTICS PLC
More recommendations
Financials (USD)
Sales 2022 15,8 M - -
Net income 2022 -155 M - -
Net cash 2022 269 M - -
P/E ratio 2022 -1,09x
Yield 2022 -
Capitalization 307 M 307 M -
EV / Sales 2022 2,45x
EV / Sales 2023 3,09x
Nbr of Employees 326
Free-Float 9,68%
Chart AUTOLUS THERAPEUTICS PLC
Duration : Period :
Autolus Therapeutics plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AUTOLUS THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 1,85 $
Average target price 9,56 $
Spread / Average Target 417%
EPS Revisions
Managers and Directors
Christian Martin Itin Chief Executive Officer & Director
Lucinda Crabtree Chief Financial Officer
John H. Johnson Non-Executive Chairman
Martin PulÚ Chief Scientific Officer & Senior Vice President
David Brochu Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
AUTOLUS THERAPEUTICS PLC-42.39%272
VERTEX PHARMACEUTICALS44.62%82 480
REGENERON PHARMACEUTICALS, INC.21.02%81 748
BIONTECH SE-33.36%41 753
WUXI APPTEC CO., LTD.-32.53%33 492
GENMAB A/S23.08%29 964